Literature DB >> 20674566

Effects of the NOP receptor agonist Ro65-6570 on the acquisition of opiate- and psychostimulant-induced conditioned place preference in rats.

Kris Rutten1, Jean De Vry, Walter Bruckmann, Thomas M Tzschentke.   

Abstract

Activation of the Nociceptin/Orphanin FQ (NOP) receptor may have anti-abuse effects. The present study examined the consequence of NOP receptor activation on the rewarding effect of opiates and psychostimulants in the conditioned place preference task in rats. First, the motivational effect of the NOP receptor agonists Ro64-6198 (0.316-3.16 mg/kg i.p.) and Ro65-6570 (1-10mg/kg i.p.) when administered alone, was assessed. Ro65-6570 was selected for further drug combination studies since, unlike Ro64-6198, it was devoid of an intrinsic motivational effect. Next, the minimal effective dose to induce reward for the opiates heroin (0.1-3.16 mg/kg i.p.), morphine (1-10mg/kg i.p.), hydrocodone (0.316-10mg/kg i.p.), tilidine (1-31.6 mg/kg i.p.), hydromorphone (0.1-10mg/kg i.p.), and oxycodone (0.0316-10mg/kg i.p.), as well as for the psychostimulants cocaine (3.16-31.6 mg/kg i.p.) and dexamphetamine (0.316-3.16 mg/kg i.p.) in combination with Ro 65-6570 (0 or 3.16 mg/kg i.p.) was determined. All drugs produced conditioned place preference, and for opiates and cocaine, but not for dexamphetamine, the minimal effective dose was higher when combined with Ro65-6570 (3.16 mg/kg i.p.). Attenuation of the rewarding effect of tilidine (3.16 mg/kg i.p.) and oxycodone (1mg/kg i.p.) by Ro65-6570 (3.16 mg/kg i.p.) could be reversed by pre-treatment with the NOP receptor antagonist J-113397 (4.64 mg/kg i.p.), suggesting that the attenuating effect of Ro65-6570 on opiates is due to activation of the NOP receptor. Taken together, the present study suggests that activation of NOP receptors effectively attenuates the rewarding effect of opiates, but may be less effective in reducing psychostimulant-induced reward.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20674566     DOI: 10.1016/j.ejphar.2010.07.036

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  18 in total

Review 1.  Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.

Authors:  Nurulain T Zaveri
Journal:  J Med Chem       Date:  2016-03-14       Impact factor: 7.446

2.  Nociceptin receptor activation does not alter acquisition, expression, extinction and reinstatement of conditioned cocaine preference in mice.

Authors:  G C Sartor; S K Powell; H J Wiedner; C Wahlestedt; S P Brothers
Journal:  Brain Res       Date:  2015-12-03       Impact factor: 3.252

Review 3.  Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.

Authors:  W Schröder; D G Lambert; M C Ko; T Koch
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

Review 4.  Novel approaches for the treatment of psychostimulant and opioid abuse - focus on opioid receptor-based therapies.

Authors:  Chris P Bailey; Stephen M Husbands
Journal:  Expert Opin Drug Discov       Date:  2014-09-25       Impact factor: 6.098

5.  Cebranopadol Blocks the Escalation of Cocaine Intake and Conditioned Reinstatement of Cocaine Seeking in Rats.

Authors:  Giordano de Guglielmo; Alessandra Matzeu; Jenni Kononoff; Julia Mattioni; Rémi Martin-Fardon; Olivier George
Journal:  J Pharmacol Exp Ther       Date:  2017-06-23       Impact factor: 4.030

Review 6.  Using molecular imaging to understand early schizophrenia-related psychosis neurochemistry: a review of human studies.

Authors:  Christin Schifani; Sina Hafizi; Tania Da Silva; Jeremy Joseph Watts; M Saad Khan; Romina Mizrahi
Journal:  Int Rev Psychiatry       Date:  2017-12-08

7.  Genetic Deletion of the Nociceptin/Orphanin FQ Receptor in the Rat Confers Resilience to the Development of Drug Addiction.

Authors:  Marsida Kallupi; Giulia Scuppa; Giordano de Guglielmo; Girolamo Calò; Friedbert Weiss; Michael A Statnick; Linda M Rorick-Kehn; Roberto Ciccocioppo
Journal:  Neuropsychopharmacology       Date:  2016-08-26       Impact factor: 7.853

Review 8.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

Review 9.  The Nociceptin Receptor as an Emerging Molecular Target for Cocaine Addiction.

Authors:  Kabirullah Lutfy; Nurulain T Zaveri
Journal:  Prog Mol Biol Transl Sci       Date:  2015-12-23       Impact factor: 3.622

Review 10.  Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors.

Authors:  Jolien De Neve; Thomas M A Barlow; Dirk Tourwé; Frédéric Bihel; Frédéric Simonin; Steven Ballet
Journal:  RSC Med Chem       Date:  2021-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.